Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW, Lee YJ, Kim H, Ahn SY, Ahn JS, Shin HJ, Lee WS, Lee SM, Song IC, Lee HS, Park SW, Choi Y, Cho YY, Bae SH, Kim HJ, Sohn SK, Moon JH.
Baek DW, et al.
Ann Hematol. 2018 Dec;97(12):2309-2317. doi: 10.1007/s00277-018-3458-7. Epub 2018 Aug 2.
Ann Hematol. 2018.
PMID: 30073392
Clinical Trial.